Brief: Sk Bioscience In-House Developed Covid-19 Vaccine Skycovione Approved For Emergency Use Listing By Who
19/06/2023 10:31
June 19 (Reuters) - SK Bioscience Co Ltd 302440.KS :
* SK BIOSCIENCE: IN-HOUSE DEVELOPED COVID-19 VACCINE
SKYCOVIONE
APPROVED FOR EMERGENCY USE LISTING BY WHO
Source text for Eikon: ID:
Further company coverage: 302440.KS
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine